Suppliers / Théa PHARMA

Théa PHARMA

United States 3 duplicate records merged Updated 9 July 2026

Théa PHARMA is a finished-dose manufacturer based in United States. It appears in 50 regulatory filings across 4 regulators, without an active US DMF or CEP on file. Its filings concentrate with SWISSMEDIC (CH), US FDA and TITCK (TR). Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 18 October 2024 as NAI.

0
active US DMFs
0
valid CEPs
2
registered plants 1 with an FDA FEI number
50
filings across 4 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 18 October 2024 NAI US FDA
  • 6 June 2024 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Schaffhausen, Switzerland Not on file
Waltham, United States 3022351866

Filings and GMP by regulator

Regulator Filings GMP certificates
SWISSMEDIC (CH) 36 None
US FDA 7 1
TITCK (TR) 5 None
ISP (CL) 2 None

Comparing suppliers?

Choose your molecules and target markets. Théa PHARMA comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 18 October 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates